{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:50:41Z","timestamp":1793904641569,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"DOI":"10.7759\/cureus.67037","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T02:36:15Z","timestamp":1723862175000},"source":"Crossref","is-referenced-by-count":14,"title":["Emerging Gene Therapies for Alzheimer\u2019s and Parkinson\u2019s Diseases: An Overview of Clinical Trials and Promising Candidates"],"prefix":"10.7759","author":[{"given":"Will S","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.10.023","article-title":"Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist","volume":"112","author":"Litvinchuk A","year":"2024","unstructured":"Litvinchuk A, Suh JH, Guo JL, et al.. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. 2024, 112:384-403.e8. 10.1016\/j.neuron.2023.10.023","journal-title":"Neuron"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice","volume":"36","author":"Liu W","year":"2016","unstructured":"Liu W, Zhao L, Blackman B, et al.. Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. J Neurosci. 2016, 36:12425-35. 10.1523\/JNEUROSCI.2016-16.2016","journal-title":"J Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04285-3","article-title":"From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer's disease","author":"Ortega A","year":"2024","unstructured":"Ortega A, Chernicki B, Ou G, Parmar MS. From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer's disease. Mol Neurobiol. 2024, 10.1007\/s12035-024-04285-3","journal-title":"Mol Neurobiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18362","article-title":"The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer's disease","volume":"13","author":"Hobday AL","year":"2021","unstructured":"Hobday AL, Parmar MS. The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer's disease. Cureus. 2021, 13:e18362. 10.7759\/cureus.18362","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","unstructured":"2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024, 20.3708-821. 10.1002\/alz.13809","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184262","article-title":"The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome","volume":"12","author":"Park HJ","year":"2017","unstructured":"Park HJ, Ryu D, Parmar M, Giasson BI, McFarland NR. The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. PLoS One. 2017, 12:e0184262. 10.1371\/journal.pone.0184262","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2017.10.015","article-title":"Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1\/2-dependent mechanism","volume":"54","author":"Allen EN","year":"2018","unstructured":"Allen EN, Potdar S, Tapias V, Parmar M, Mizuno CS, Rimando A, Cavanaugh JE. Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1\/2-dependent mechanism. J Nutr Biochem. 2018, 54:77-86. 10.1016\/j.jnutbio.2017.10.015","journal-title":"J Nutr Biochem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-017-2073-z","article-title":"Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells","volume":"92","author":"Potdar S","year":"2018","unstructured":"Potdar S, Parmar MS, Ray SD, Cavanaugh JE. Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. Arch Toxicol. 2018, 92:669-77. 10.1007\/s00204-017-2073-z","journal-title":"Arch Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong MJ","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020, 323:548-60. 10.1001\/jama.2019.22360","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07599-1","article-title":"From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges","author":"Grote J","year":"2024","unstructured":"Grote J, Patel N, Bates C, Parmar MS. From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges. Neurol Sci. 2024, 10.1007\/s10072-024-07599-1","journal-title":"Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.00725","article-title":"Gene therapy strategies targeting aging-related diseases","volume":"14","author":"Yu J","year":"2023","unstructured":"Yu J, Li T, Zhu J. Gene therapy strategies targeting aging-related diseases. Aging Dis. 2023, 14:398-417. 10.14336\/AD.2022.00725","journal-title":"Aging Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1566523222666220328142427","article-title":"Gene therapy, a potential therapeutic tool for neurological and neuropsychiatric disorders: applications, challenges and future perspective","volume":"23","author":"Mani S","year":"2023","unstructured":"Mani S, Jindal D, Singh M. Gene therapy, a potential therapeutic tool for neurological and neuropsychiatric disorders: applications, challenges and future perspective. Curr Gene Ther. 2023, 23:20-40. 10.2174\/1566523222666220328142427","journal-title":"Curr Gene Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn DB","year":"2023","unstructured":"Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Ther. 2023, 30:738-46. 10.1038\/s41434-023-00390-5","journal-title":"Gene Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling Q","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023, 22:789-806. 10.1038\/s41573-023-00766-7","journal-title":"Nat Rev Drug Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.988914","article-title":"Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases","volume":"15","author":"Zhou K","year":"2022","unstructured":"Zhou K, Han J, Wang Y, Zhang Y, Zhu C. Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases. Front Mol Neurosci. 2022, 15:988914. 10.3389\/fnmol.2022.988914","journal-title":"Front Mol Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease","volume":"29","author":"Rosenberg JB","year":"2018","unstructured":"Rosenberg JB, Kaplitt MG, De BP, et al.. AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease. Hum Gene Ther Clin Dev. 2018, 29:24-47. 10.1089\/humc.2017.231","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/v16030442","article-title":"Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights","volume":"16","author":"Lopez-Gordo E","year":"2024","unstructured":"Lopez-Gordo E, Chamberlain K, Riyad JM, Kohlbrenner E, Weber T. Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights. Viruses. 2024, 16:10.3390\/v16030442","journal-title":"Viruses"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.03.017","article-title":"CRISPR\/Cas9 system and its applications in nervous system diseases","volume":"11","author":"Jiang H","year":"2024","unstructured":"Jiang H, Tang M, Xu Z, et al.. CRISPR\/Cas9 system and its applications in nervous system diseases. Genes Dis. 2024, 11:675-86. 10.1016\/j.gendis.2023.03.017","journal-title":"Genes Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent M","year":"2024","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024, 13:800. 10.3390\/cells13100800","journal-title":"Cells"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease","volume":"34","author":"Heiss JD","year":"2019","unstructured":"Heiss JD, Lungu C, Hammoud DA, et al.. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease. Mov Disord. 2019, 34:1073-8. 10.1002\/mds.27724","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206690","article-title":"Phase 1b safety and preliminary efficacy of bilateral intraputaminal delivery of AAV2 GDNF (AB-1005) in participants with mild or moderate Parkinson\u2019s disease (N2.001)","volume":"102","author":"Van Laar A","year":"2024","unstructured":"Van Laar A, Christine C, Merola A, et al.. Phase 1b safety and preliminary efficacy of bilateral intraputaminal delivery of AAV2 GDNF (AB-1005) in participants with mild or moderate Parkinson\u2019s disease (N2.001). Neurology. 2024, 102:6786. 10.1212\/WNL.0000000000206690","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease","volume":"85","author":"Christine CW","year":"2019","unstructured":"Christine CW, Bankiewicz KS, Van Laar AD, et al.. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019, 85:704-14. 10.1002\/ana.25450","journal-title":"Ann Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27993","article-title":"Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's disease","volume":"35","author":"Nutt JG","year":"2020","unstructured":"Nutt JG, Curtze C, Hiller A, et al.. Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's disease. Mov Disord. 2020, 35:851-8. 10.1002\/mds.27993","journal-title":"Mov Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012952","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial","volume":"98","author":"Christine CW","year":"2022","unstructured":"Christine CW, Richardson RM, Van Laar AD, et al.. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. Neurology. 2022, 98:e40-50. 10.1212\/WNL.0000000000012952","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-322904","article-title":"Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease","volume":"91","author":"Richardson RM","year":"2020","unstructured":"Richardson RM, Bankiewicz KS, Christine CW, et al.. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020, 91:1210-8. 10.1136\/jnnp-2020-322904","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12697","article-title":"Gene therapy for neurotransmitter-related disorders","volume":"47","author":"Chu WS","year":"2024","unstructured":"Chu WS, Ng J, Waddington SN, Kurian MA. Gene therapy for neurotransmitter-related disorders. J Inherit Metab Dis. 2024, 47:176-91. 10.1002\/jimd.12697","journal-title":"J Inherit Metab Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt PA","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, et al.. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10:309-19. 10.1016\/S1474-4422(11)70039-4","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt MG","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, et al.. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007, 369:2097-105. 10.1016\/S0140-6736(07)60982-9","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease","volume":"2","author":"Niethammer M","year":"2017","unstructured":"Niethammer M, Tang CC, LeWitt PA, et al.. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. JCI Insight. 2017, 2:e90133. 10.1172\/jci.insight.90133","journal-title":"JCI Insight"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer's disease","volume":"377","author":"Ballard C","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011, 377:1019-31. 10.1016\/S0140-6736(10)61349-9","journal-title":"Lancet"},{"key":"ref31","article-title":"Aducanumab","author":"Padda IS","year":"2024","unstructured":"Padda IS, Parmar M. Aducanumab. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings J","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al.. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023, 10:362-77. 10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi M","year":"2022","unstructured":"Shi M, Chu F, Zhu F, Zhu J. Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab. Front Aging Neurosci. 2022, 14:870517. 10.3389\/fnagi.2022.870517","journal-title":"Front Aging Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.024","article-title":"APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease","volume":"32","author":"Jackson RJ","year":"2024","unstructured":"Jackson RJ, Keiser MS, Meltzer JC, et al.. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Mol Ther. 2024, 32:1373-86. 10.1016\/j.ymthe.2024.03.024","journal-title":"Mol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.044","article-title":"ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion","volume":"168","author":"Huang YA","year":"2017","unstructured":"Huang YA, Zhou B, Wernig M, S\u00fcdhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion. Cell. 2017, 168:427-441.e21. 10.1016\/j.cell.2016.12.044","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi Y","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, et al.. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017, 549:523-7. 10.1038\/nature24016","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)33996-X","article-title":"Gene delivery of APOE2 reduces amyloid pathology in transgenic mouse models of Alzheimer's disease","volume":"23","author":"Zhao L","year":"2015","unstructured":"Zhao L, Gottesdiener AJ, Parmar M, et al.. Gene delivery of APOE2 reduces amyloid pathology in transgenic mouse models of Alzheimer's disease. Mol Ther. 2015, 23:S154. 10.1016\/S1525-0016(16)33996-X","journal-title":"Mol Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.03.004","article-title":"ApoE cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias","volume":"110","author":"Martens YA","year":"2022","unstructured":"Martens YA, Zhao N, Liu CC, et al.. ApoE cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron. 2022, 110:1304-17. 10.1016\/j.neuron.2022.03.004","journal-title":"Neuron"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101594","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease","volume":"59","author":"Parhizkar S","year":"2022","unstructured":"Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. Semin Immunol. 2022, 59:101594. 10.1016\/j.smim.2022.101594","journal-title":"Semin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models","volume":"44","author":"Zhao L","year":"2016","unstructured":"Zhao L, Gottesdiener AJ, Parmar M, et al.. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiol Aging. 2016, 44:159-72. 10.1016\/j.neurobiolaging.2016.04.020","journal-title":"Neurobiol Aging"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.925991","article-title":"Brain-derived neurotrophic factor: a connecting link between nutrition, lifestyle, and Alzheimer's disease","volume":"16","author":"Xue B","year":"2022","unstructured":"Xue B, Waseem SM, Zhu Z, et al.. Brain-derived neurotrophic factor: a connecting link between nutrition, lifestyle, and Alzheimer's disease. Front Neurosci. 2022, 16:925991. 10.3389\/fnins.2022.925991","journal-title":"Front Neurosci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara AH","year":"2009","unstructured":"Nagahara AH, Merrill DA, Coppola G, et al.. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009, 15:331-7. 10.1038\/nm.1912","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-018-0010-2","article-title":"MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates","volume":"25","author":"Nagahara AH","year":"2018","unstructured":"Nagahara AH, Wilson BR, Ivasyk I, et al.. MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther. 2018, 25:104-14. 10.1038\/s41434-018-0010-2","journal-title":"Gene Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201200245","article-title":"Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer","volume":"4","author":"Bernardes de Jesus B","year":"2012","unstructured":"Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med. 2012, 4:691-704. 10.1002\/emmm.201200245","journal-title":"EMBO Mol Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101982","article-title":"Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice","volume":"11","author":"Whittemore K","year":"2019","unstructured":"Whittemore K, Derevyanko A, Martinez P, Serrano R, Pumarola M, Bosch F, Blasco MA. Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice. Aging (Albany NY). 2019, 11:2916-48. 10.18632\/aging.101982","journal-title":"Aging (Albany NY)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.367","article-title":"Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer's disease identifies a need for improved vector delivery","volume":"31","author":"Castle MJ","year":"2020","unstructured":"Castle MJ, Baltan\u00e1s FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH. Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer's disease identifies a need for improved vector delivery. Hum Gene Ther. 2020, 31:415-22. 10.1089\/hum.2019.367","journal-title":"Hum Gene Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii MS","year":"2018","unstructured":"Rafii MS, Tuszynski MH, Thomas RG, et al.. Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2018, 75:834-41. 10.1001\/jamaneurol.2018.0233","journal-title":"JAMA Neurol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1807","article-title":"Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease","volume":"72","author":"Tuszynski MH","year":"2015","unstructured":"Tuszynski MH, Yang JH, Barba D, et al.. Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol. 2015, 72:1139-47. 10.1001\/jamaneurol.2015.1807","journal-title":"JAMA Neurol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii MS","year":"2014","unstructured":"Rafii MS, Baumann TL, Bakay RA, et al.. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014, 10:571-81. 10.1016\/j.jalz.2013.09.004","journal-title":"Alzheimers Dement"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/nm1239","article-title":"A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski MH","year":"2005","unstructured":"Tuszynski MH, Thal L, Pay M, et al.. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005, 11:551-5. 10.1038\/nm1239","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.90.15_supplement.P3.049","article-title":"Rab8a protects against alpha-synuclein toxicity in a rat model of Parkinsonism (P3","volume":"90","author":"McFarland N","year":"2018","unstructured":"McFarland N, Parmar M, Park H-J, Ryu D, Powell L, Foels R, Anagnostis S. Rab8a protects against alpha-synuclein toxicity in a rat model of Parkinsonism (P3. Neurology. 2018, 90:10.1212\/WNL.90.15_supplement.P3.049","journal-title":"Neurology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2018.07.005","article-title":"The reversible effects of glial cell line-derived neurotrophic factor (GDNF) in the human brain","volume":"53","author":"Ayanlaja AA","year":"2018","unstructured":"Ayanlaja AA, Zhang B, Ji G, Gao Y, Wang J, Kanwore K, Gao D. The reversible effects of glial cell line-derived neurotrophic factor (GDNF) in the human brain. Semin Cancer Biol. 2018, 53:212-22. 10.1016\/j.semcancer.2018.07.005","journal-title":"Semin Cancer Biol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.014","article-title":"GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution","volume":"147","author":"Grondin R","year":"2019","unstructured":"Grondin R, Littrell OM, Zhang Z, et al.. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution. Neuropharmacology. 2019, 147:28-36. 10.1016\/j.neuropharm.2018.05.014","journal-title":"Neuropharmacology"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2022.36.S1.L8063","article-title":"DNSP\u201011 reduces 6\u2010OHDA\u2010induced caspase 3\/7 activation in an SH\u2010SY5Y cell model: potential Role of ERK signaling pathway?","volume":"36","author":"Parmar MS","year":"2022","unstructured":"Parmar MS, Allen E, Narain S, Khanna D, Cavanaugh J. DNSP\u201011 reduces 6\u2010OHDA\u2010induced caspase 3\/7 activation in an SH\u2010SY5Y cell model: potential Role of ERK signaling pathway?. FASEB Journal. 2022, 36:10.1096\/fasebj.2022.36.S1.L8063","journal-title":"FASEB Journal"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.09.031","article-title":"Role of ERK1, 2, and 5 in dopamine neuron survival during aging","volume":"35","author":"Parmar MS","year":"2014","unstructured":"Parmar MS, Jaumotte JD, Wyrostek SL, Zigmond MJ, Cavanaugh JE. Role of ERK1, 2, and 5 in dopamine neuron survival during aging. Neurobiol Aging. 2014, 35:669-79. 10.1016\/j.neurobiolaging.2013.09.031","journal-title":"Neurobiol Aging"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1159\/000334527","article-title":"Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease","volume":"11","author":"Du Y","year":"2013","unstructured":"Du Y, Zhang X, Tao Q, Chen S, Le W. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease. Neurodegener Dis. 2013, 11:113-28. 10.1159\/000334527","journal-title":"Neurodegener Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(97)01100-1","article-title":"Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease","volume":"777","author":"Lapchak PA","year":"1997","unstructured":"Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res. 1997, 777:153-60. 10.1016\/s0006-8993(97)01100-1","journal-title":"Brain Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2004.06.029","article-title":"Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease","volume":"134","author":"Zheng JS","year":"2005","unstructured":"Zheng JS, Tang LL, Zheng SS, et al.. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Brain Res Mol Brain Res. 2005, 134:155-61. 10.1016\/j.molbrainres.2004.06.029","journal-title":"Brain Res Mol Brain Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-12-04942.2002","article-title":"Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration","volume":"22","author":"Palfi S","year":"2002","unstructured":"Palfi S, Leventhal L, Chu Y, et al.. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002, 22:4942-54. 10.1523\/JNEUROSCI.22-12-04942.2002","journal-title":"J Neurosci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.10.004","article-title":"Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain","volume":"48","author":"Kells AP","year":"2012","unstructured":"Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis. 2012, 48:228-35. 10.1016\/j.nbd.2011.10.004","journal-title":"Neurobiol Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio EA","year":"2013","unstructured":"Salegio EA, Samaranch L, Kells AP, et al.. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 2013, 20:348-52. 10.1038\/gt.2012.27","journal-title":"Gene Ther"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169965","article-title":"Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial","volume":"12","author":"Ciesielska A","year":"2017","unstructured":"Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS One. 2017, 12:e0169965. 10.1371\/journal.pone.0169965","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1089\/10430340050083243","article-title":"Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease","volume":"11","author":"Shen Y","year":"2000","unstructured":"Shen Y, Muramatsu SI, Ikeguchi K, et al.. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther. 2000, 11:1509-19. 10.1089\/10430340050083243","journal-title":"Hum Gene Ther"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.17-2527","article-title":"Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors","volume":"9","author":"Fan DS","year":"1998","unstructured":"Fan DS, Ogawa M, Fujimoto KI, et al.. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther. 1998, 9:2527-35. 10.1089\/hum.1998.9.17-2527","journal-title":"Hum Gene Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.05.005","article-title":"Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC","volume":"14","author":"Bankiewicz KS","year":"2006","unstructured":"Bankiewicz KS, Forsayeth J, Eberling JL, et al.. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006, 14:564-70. 10.1016\/j.ymthe.2006.05.005","journal-title":"Mol Ther"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1089\/10430340252792486","article-title":"Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes","volume":"13","author":"Muramatsu S","year":"2002","unstructured":"Muramatsu S, Fujimoto K, Ikeguchi K, et al.. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther. 2002, 13:345-54. 10.1089\/10430340252792486","journal-title":"Hum Gene Ther"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine CW","year":"2009","unstructured":"Christine CW, Starr PA, Larson PS, et al.. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009, 73:1662-9. 10.1212\/WNL.0b013e3181c29356","journal-title":"Neurology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer G","year":"2012","unstructured":"Mittermeyer G, Christine CW, Rosenbluth KH, et al.. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther. 2012, 23:377-81. 10.1089\/hum.2011.220","journal-title":"Hum Gene Ther"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease","volume":"18","author":"Muramatsu S","year":"2010","unstructured":"Muramatsu S, Fujimoto K, Kato S, et al.. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010, 18:1731-5. 10.1038\/mt.2010.135","journal-title":"Mol Ther"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600364","article-title":"Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism","volume":"27","author":"Emborg ME","year":"2007","unstructured":"Emborg ME, Carbon M, Holden JE, et al.. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab. 2007, 27:501-9. 10.1038\/sj.jcbfm.9600364","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust KD","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009, 27:59-65. 10.1038\/nbt.1515","journal-title":"Nat Biotechnol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.12.006","article-title":"Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning","volume":"20","author":"Nonnenmacher M","year":"2021","unstructured":"Nonnenmacher M, Wang W, Child MA, et al.. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol Ther Methods Clin Dev. 2021, 20:366-78. 10.1016\/j.omtm.2020.12.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry E","year":"2019","unstructured":"Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019, 101:839-62. 10.1016\/j.neuron.2019.02.017","journal-title":"Neuron"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00419-9","article-title":"The estimated annual financial impact of gene therapy in the United States","volume":"30","author":"Wong CH","year":"2023","unstructured":"Wong CH, Li D, Wang N, Gruber J, Lo AW, Conti RM. The estimated annual financial impact of gene therapy in the United States. Gene Ther. 2023, 30:761-73. 10.1038\/s41434-023-00419-9","journal-title":"Gene Ther"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v14i3.5500","article-title":"Cost-effectiveness of a hypothetical gene therapy for Alzheimer's disease: a Markov simulation analysis","volume":"14","author":"Kieu C","year":"2023","unstructured":"Kieu C, Look KA. Cost-effectiveness of a hypothetical gene therapy for Alzheimer's disease: a Markov simulation analysis. Innov Pharm. 2023, 14:10.24926\/iip.v14i3.5500","journal-title":"Innov Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268812-emerging-gene-therapies-for-alzheimers-and-parkinsons-diseases-an-overview-of-clinical-trials-and-promising-candidates","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T02:36:20Z","timestamp":1723862180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268812-emerging-gene-therapies-for-alzheimers-and-parkinsons-diseases-an-overview-of-clinical-trials-and-promising-candidates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":76,"URL":"https:\/\/doi.org\/10.7759\/cureus.67037","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}